AIDSWEEKLY Plus; Monday, September 12, 2005
Staff Medical Writers

"The significantly higher surface expression of the surface heat-shock protein receptor CD91 on monocytes of human immunodeficiency virus type-1 (HIV-1)-infected, long-term nonprogressors suggests that HIV-1 antigen uptake and cross-presentation mediated by CD91 may contribute to host anti-HIV-1 defenses and play a role in protection against HIV-1 infection.

"To investigate this further, we performed phenotypic analysis to compare CD91 surface expression on CD14+ monocytes derived from a cohort of HIV-1-exposed seronegative (ESN) subjects, their seropositive (SP) partners, and healthy HIV-1-unexposed seronegative (USN) subjects," researchers in England report.

"The median fluorescent intensity (MFI) of CD91 on CD14+ monocytes was significantly higher in ESN compared with SP (p=0.028) or USN (p=0.007), as well as in SP compared with USN subjects (p=0.018).

"CD91 MFI was not normalized in SP subjects on highly active antiretroviral therapy (HAART) despite sustainable, undetectable plasma viremia," wrote A. Kebba and colleagues at Chelsea & Westminster Hospital in London.

"Data in three SP subjects experiencing viral rebounds following interruption of HAART showed low CD91 MFI comparable with levels in USN subjects," scientists said.

Kebba concluded, "There was a significant positive correlation between CD91 MFI and CD8+ T cell counts in HAART-naive SP subjects (r=0.7, p=0.015). Increased surface expression of CD91 on CD14+ monocytes is associated with the apparent HIV-1 resistance that is observed in ESN subjects."

Kebba and colleagues published their study in the Journal of Leukocyte Biology (Expression of the common heat-shock protein receptor CD91 is increased on monocytes of exposed yet HIV-1-seronegative subjects. J Leukoc Biol. 2005 Jul;78(1):37-42.

For additional information, contact A. Kebba, Chelsea & Westminster Hospital, Dept. Immunology, Imperial College, 369 Fulham Rd., London SW10 9NH, England.

Publisher contact information for the Journal of Leukocyte Biology is: Federation American Society Experimental Biology, 9650 Rockville Pike, Bethesda, MD 20814-3998, USA.

Keywords: London, England, HIV/AIDS, CD91 Expression, Exposed HIV-1 Seronegative, HAART, Viral Load.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Kebba A, Stebbing J, Rowland S, et al. Expression of the common heat-shock protein receptor CD91 is increased on monocytes of exposed yet HIV-1-seronegative subjects, J Leukoc Biol. 2005 Jul;78(1):37-42.

PubMED Related articles Search

050912
AW050905

Copyright © 2005 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.